```
 => File reg
=> s (anionic detergent or cationic detergent or non-ionic detergent or
zwitterionic detergent)/cn
             0 ANIONIC DETERGENT/CN
             0 CATIONIC DETERGENT/CN
             0 NON-IONIC DETERGENT/CN
             0 ZWITTERIONIC DETERGENT/CN
L1           0 (ANIONIC DETERGENT OR CATIONIC DETERGENT OR NON-IONIC DETERGENT
               OR ZWITTERIONIC DETERGENT)/CN

=> s (organic solvent or acetone or alcohol)/cn
             0 ORGANIC SOLVENT/CN
             1 ACETONE/CN
             1 ALCOHOL/CN
L2           2 (ORGANIC SOLVENT OR ACETONE OR ALCOHOL)/CN

=> s (cholate or deoxycholate)/cn
             0 CHOLATE/CN
             0 DEOXYCHOLATE/CN
L3           0 (CHOLATE OR DEOXYCHOLATE)/CN

=> File .Biotech
=> s (anionic detergent or cationic detergent or non-ionic detergent or
zwitterionic detergent)
L4       13872 (ANIONIC DETERGENT OR CATIONIC DETERGENT OR NON-IONIC DETERGENT
               OR ZWITTERIONIC DETERGENT)

=> s (organic solvent or acetone or alcohol and l2)
L5      783059 (ORGANIC SOLVENT OR ACETONE OR ALCOHOL AND L2)

=> s l4 and l5
L6        1502 L4 AND L5

=> s l6 and (cholate or deoxycholate)
L7          88 L6 AND (CHOLATE OR DEOXYCHOLATE)

=> s l7 and (protein(3l)prepar? or mak? or purif? or precipitat? or aggregat?)
   6 FILES SEARCHED...
L8          87 L7 AND (PROTEIN(3L) PREPAR? OR MAK? OR PURIF? OR PRECIPITAT?
               OR AGGREGAT?)

=> s l8 and (solubiliz? or neutraliz? agent)
L9          45 L8 AND (SOLUBILIZ? OR NEUTRALIZ? AGENT)

=> s l9 and (sodium dodecyl sulfate or SDS)
L10         34 L9 AND (SODIUM DODECYL SULFATE OR SDS)

=> s l10 and (salt#)
L11         30 L10 AND (SALT#)

=> s l11 and (polysaccharide)
L12          5 L11 AND (POLYSACCHARIDE)

=> d l12 1-5 bib ab

L12  ANSWER 1 OF 5  USPATFULL on STN
AN     2003:134060  USPATFULL
TI     Viral vaccine composition, process, and methods of use
IN     Jira, Vic, El Monte, CA, UNITED STATES
       Jirathitikal, Vichai, Chachoengsao, THAILAND
PI     US 2003092145      A1   20030515
AI     US 2001-935344     A1   20010823 (9)
PRAI   US 2000-227520P     20000824 (60)
DT     Utility
```

FS APPLICATION
LREP BLANK ROME COMISKY & MCCAULEY LLP, THE FARRAGUT BUILDING, SUITE 1000, 900 17TH STREET, NW, WASHINGTON, DC, 20006
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3165
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition for treating or preventing virus-induced infections is described, along with a process of producing the composition and methods of the composition's use. The composition comprises viral pathogen-infected cell or tissue, or malignantly or immunologically aberrant cells or tissues which has been reduced and/or denatured. The preferred composition is administered across a mucosal surface of an animal suffering or about suffer from infection. The composition is administered as preventive or therapeutic vaccine.

L12 ANSWER 2 OF 5 USPATFULL on STN
AN 2001:188434 USPATFULL
TI Agent for protein **precipitation**, a method of protein **precipitation**, a method of protein assay using protein **precipitation** agent, and a kit for protein assay
IN Alam, Aftab, St. Louis, MO, United States
PI US 2001034066 A1 20011025
AI US 2001-842838 A1 20010427 (9)
RLI Continuation-in-part of Ser. No. US 1998-223738, filed on 31 Dec 1998, PENDING Division of Ser. No. US 1997-965873, filed on 7 Nov 1997, GRANTED, Pat. No. US 5900376 Division of Ser. No. US 2000-507977, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-249499, filed on 12 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 1997-965873, filed on 7 Nov 1997, GRANTED, Pat. No. US 5900376
DT Utility
FS APPLICATION
LREP ARENT FOX KINTNER PLOTKIN & KAHN, 1050 CONNECTICUT AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20036
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1323
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of **protein precipitation**, concentration and removal of non-**protein** agents from the **protein** solution wherein the **protein** solution is treated with a **protein-precipitation** agent containing an acidic agent, a **salt** and a **precipitate** forming agent. After **precipitation**, the **protein precipitate** is washed with a water miscible **organic solvent** agent to remove non-**protein** agents present in the **protein precipitate**.

L12 ANSWER 3 OF 5 USPATFULL on STN
AN 1998:65352 USPATFULL
TI GTPase activating protein fragments
IN McCormick, Francis P., Berkeley, CA, United States
Wong, Gail L., Oakland, CA, United States
Polakis, Paul G., San Francisco, CA, United States
Rubinfeld, Bonnee, Danville, CA, United States
PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 5763573 19980609
AI US 1995-380206 19950130 (8)
RLI Continuation of Ser. No. US 1993-138880, filed on 18 Oct 1993, now abandoned which is a continuation of Ser. No. US 1991-776878, filed on 16 Oct 1991, now abandoned which is a continuation of Ser. No. US 1989-396910, filed on 21 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-260807, filed on 21 Oct 1988,

now abandoned which is a continuation-in-part of Ser. No. US 1988-230761, filed on 10 Aug 1988, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Guzo, David
LREP Gass, David A., McGarrigle, Jr., Philip L., Blackburn, Robert P.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 29 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 2192
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptides, that inhibit GAP stimulated ras p21 hydrolysis of GTP; peptides that mediate dissociation of GDP from ras p21-GTP complex; and antibodies to the peptides are described. These peptides are useful as cancer diagnostics and therapeutics, particularly to detect cancer cells with an over expression of normal or oncogenic ras p21 **protein** and to treat cancer caused by ras oncogene. Methods for assaying products of oncogenes using the described peptides and antibodies are also disclosed. Method for treating cancer caused by ras oncogenes is also disclosed.

L12 ANSWER 4 OF 5 USPATFULL on STN
AN 91:40541 USPATFULL
TI Treatment of bleeding disorders using lipid-free tissue factor protein
IN O'Brien, Donogh P., Bromley, England
Vehar, Gordon A., San Carlos, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5017556 19910521
AI US 1989-320876 19890308 (7)
RLI Continuation of Ser. No. US 1987-110255, filed on 20 Oct 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-926977, filed on 4 Nov 1986, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Kepplinger, Esther L.; Assistant Examiner: Kushan, Jeff
LREP Hensley, Max D., Winter, Daryl B.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 864
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method and therapeutic composition for the treatment of bleeding disorders, for example those characterized by a tendency toward hemorrhage or a hypercoagulative state, by the administration of tissue factor protein or antagonists thereof.

L12 ANSWER 5 OF 5 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
AN 2002-170918 [22] WPIDS
CR 1999-311709 [26]
DNN N2002-130028 DNC C2002-052716
TI **Preparation** of **protein** sample solution involves treating **protein** solution with **protein-precipitation** agents containing acidic agent, **salt** and **precipitate** forming agent.
DC B04 J04 S03
IN ALAM, A
PA (ALAM-I) ALAM A
CYC 1
PI US 2001034066 A1 20011025 (200222)* 23p
ADT US 2001034066 A1 CIP of US 1997-965873 19971107, Div ex US 1997-965873 19971107, CIP of US 1998-223738 19981231, CIP of US 1999-249499 19990212, Div ex US 2000-507977 20000222, US 2001-842838 20010427
FDT US 2001034066 A1 CIP of US 5900376, Div ex US 5900376

PRAI US 2000-507977 20000222; US 1997-965873 19971107; US 1998-223738 19981231; US 1999-249499 19990212; US 2001-842838 20010427

AB US2001034066 A UPAB: 20020409

NOVELTY - A **protein** sample solution is **prepared** by treating a **protein** solution with a **protein-precipitation** agent containing an acidic agent, **salt** and a **precipitate** forming agent. After **precipitation**, the **protein precipitate** is washed with a water miscible **organic solvent** agent to remove non-**protein** agents present in the **protein precipitate**.

DETAILED DESCRIPTION - **Preparation** of **protein** sample solution for analysis involves:

(a) treating the **protein** sample solution with an acidic agent(s), such as, **salt** and **precipitate**-forming agent;

(b) centrifuging the **protein** sample solution at least one once to form a tight pellet at the bottom of the tube, remove and discard the supernatant and cooled a **protein** pellet;

(c) suspending and mixing the **protein** pellet at least once in a medium, such as, a mixture of aqueous-**organic solvent** and **organic solvent**;

(d) centrifuging the **protein** pellet suspension and collecting the **protein** pellet; and

(e) suspending the **protein** pellet in a **protein** pellet **solubilization** reagent buffer.

The reagent buffer is provided with an acid **neutralizing agent** in a sufficient amount to neutralize the acid captured in the **protein** pellet to facilitate a desired **protein solubilization**. The **protein** sample solution contains non-**protein** agents, such as, **anionic detergent**, **cationic detergent**, **non-ionic detergent**, **zwitterionic detergent**, sulfobutane, lipid, natural product, **salt** or common laboratory agent. After **preparing** the **protein** sample, the **protein** in the sample is recovered and is free from non-**protein** agents originally present in the sample.

An INDEPENDENT CLAIM is also included for a method of total **protein** assay comprising:

(i) treating the **protein** sample solution with an acidic agent;

(ii) centrifuging the **protein** sample solution to form a tight pellet at the bottom of the tube, removing and discarding the supernatant and collecting the **protein** pellet;

(iii) suspending the **protein** pellet of step (b) with alkaline reagents of a **protein** assay to produce a characteristic **protein** reaction; and

(iv) comparing the color density of the **protein** color reaction with the color density of a **protein** reaction of known **protein** concentration.

USE - For **preparing protein** sample solution.

ADVANTAGE - The invention is rapid and results in quantitative recovery of **protein** after the procedure. The interference from non-**protein** agents present in the **protein** solutions containing detergents is developed.

Dwg.0/10

```
=> s l11 and (protein assay)
L13           8 L11 AND (PROTEIN ASSAY)

=> d l13 1-8 bib ab

L13  ANSWER 1 OF 8  USPATFULL on STN
AN     2001:188434  USPATFULL
TI     Agent for protein precipitation, a method of protein
       precipitation, a method of protein assay
```

using protein **precipitation** agent, and a kit for **protein assay**
IN Alam, Aftab, St. Louis, MO, United States
PI US 2001034066 A1 20011025
AI US 2001-842838 A1 20010427 (9)
RLI Continuation-in-part of Ser. No. US 1998-223738, filed on 31 Dec 1998, PENDING Division of Ser. No. US 1997-965873, filed on 7 Nov 1997, GRANTED, Pat. No. US 5900376 Division of Ser. No. US 2000-507977, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-249499, filed on 12 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 1997-965873, filed on 7 Nov 1997, GRANTED, Pat. No. US 5900376
DT Utility
FS APPLICATION
LREP ARENT FOX KINTNER PLOTKIN & KAHN, 1050 CONNECTICUT AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20036
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1323
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of **protein precipitation**, concentration and removal of non-**protein** agents from the **protein** solution wherein the **protein** solution is treated with a **protein-precipitation** agent containing an acidic agent, a **salt** and a **precipitate** forming agent. After **precipitation**, the **protein precipitate** is washed with a water miscible **organic solvent** agent to remove non-**protein** agents present in the **protein precipitate**.

L13 ANSWER 2 OF 8 USPATFULL on STN
AN 2001:1634 USPATFULL
TI gp75 as a tumor vaccine for melanoma
IN Houghton, Alan N., New York, NY, United States
Vijayasaradhi, Setaluri, New York, NY, United States
PA Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)
PI US 6168946 B1 20010102
AI US 1995-409794 19950324 (8)
RLI Continuation of Ser. No. US 952620, now abandoned Continuation-in-part of Ser. No. US 1990-497371, filed on 22 Mar 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Allen, Marianne P.
LREP White, John P.Cooper & Dunham LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1082
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an isolated nucleic acid molecule whose sequence encodes the amino acid sequence for gp75 or a fragment thereof. The present invention further provides an isolated cDNA molecule of the gp75 nucleic acid molecule or a fragment thereof and the amino acid sequence derived therefrom. This invention also provides vaccines for stimulating or enhancing in a subject to whom the vaccine is administered production of antibodies directed against gp75. This invention further provides methods using the vaccines of this invention for stimulating or enhancing production of antibodies against gp75 as well as for treating, preventing or delaying the recurrence of cancer.

L13 ANSWER 3 OF 8 USPATFULL on STN
AN 1999:163833 USPATFULL
TI Human tissue factor related DNA segments polypeptides and antibodies
IN Edgington, Thomas S., La Jolla, CA, United States

Morrissey, James H., Oklahoma City, OK, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 6001978 19991214
AI US 1997-844806 19970422 (8)
RLI Division of Ser. No. US 1992-880079, filed on 29 Apr 1992, now patented, Pat. No. US 5622931 which is a division of Ser. No. US 1988-165939, filed on 9 Mar 1988, now patented, Pat. No. US 5223427 which is a continuation-in-part of Ser. No. US 1987-67103, filed on 25 Jun 1987, now patented, Pat. No. US 5110730 which is a continuation-in-part of Ser. No. US 1987-33047, filed on 31 Mar 1987, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Budens, Robert D.
LREP Fitting, Thomas, Holmes, Emily
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 3241
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB DNA segments that include DNA sequences defining a structural gene coding for a human tissue factor heavy chain **protein** and a precursor form of that **protein** are disclosed. Recombinant DNA molecules capable of expressing a human tissue factor heavy chain **protein** are also disclosed. Further disclosed are human tissue factor heavy chain binding site polypeptide analogs as well as methods for their use.

L13 ANSWER 4 OF 8 USPATFULL on STN
AN 97:33726 USPATFULL
TI Human tissue factor related DNA segments, polypeptides and antibodies
IN Edgington, Thomas S., La Jolla, CA, United States
Morrissey, James H., Oklahoma City, OK, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 5622931 19970422
AI US 1992-880079 19920429 (7)
RLI Division of Ser. No. US 1988-165939, filed on 9 Mar 1988, now patented, Pat. No. US 5223427 which is a continuation-in-part of Ser. No. US 1987-67103, filed on 25 Jun 1987, now patented, Pat. No. US 5110730 which is a continuation-in-part of Ser. No. US 1987-33047, filed on 31 Mar 1987, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Carlson, K. Cochrane
LREP Fitting, Thomas
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 22 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 3119
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB DNA segments that include DNA sequences defining a structural gene coding for a human tissue factor heavy chain **protein** and a precursor form of that **protein** are disclosed. Recombinant DNA molecules capable of expressing a human tissue factor heavy chain **protein** are also disclosed. Further disclosed are human tissue factor heavy chain binding site polypeptide analogs as well as methods for their use.

L13 ANSWER 5 OF 8 USPATFULL on STN
AN 95:69093 USPATFULL
TI Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
IN Edgington, Thomas S., La Jolla, CA, United States

Colman, Robert W., Moylan, PA, United States
Kappelmayer, Janos, Debrecen, Hungary
Edmunds, Jr., L. Henry, Bryn Mawr, PA, United States
Bernabei, Alvise, Philadelphia, PA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
Trustees of the University of Pennsylvania, Phialdelphia, PA, United States (U.S. corporation)
Temple University - Of the Commonwealth Systems of Higher Education, Phialdelphia, PA, United States (U.S. corporation)
PI US 5437864 19950801
AI US 1992-977281 19921116 (7)
RLI Continuation-in-part of Ser. No. US 1988-165939, filed on 9 Mar 1988, now patented, Pat. No. US 5223427 which is a continuation-in-part of Ser. No. US 1987-67103, filed on 25 Jun 1987, now patented, Pat. No. US 5110730 which is a continuation-in-part of Ser. No. US 1987-33047, filed on 31 Mar 1987, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Nucker, Christine M.; Assistant Examiner: Cunningham, T.
LREP Spensley Horn Jubas & Lubitz
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 31 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 3505
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a method of inhibiting coagulation in extracorporeal circulation in a subject, comprising administration of a therapeutically effective amount of a monoclonal antibody which inhibits the ability of tissue factor to bind to factor VII/VIIa. The method prevents complex formation between tissue factor and factor VII/VIIa and thus inhibits coagulation of blood in extracorporeal procedures such as cardiopulmonary bypass and other shunt procedures. Anti-tissue factor monoclonal antibodies produced by hybridoma cell lines TFS-5G9 or TF9-6B4 may be used in the claimed methods.

L13 ANSWER 6 OF 8 USPATFULL on STN
AN 93:52505 USPATFULL
TI Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
IN Edgington, Thomas S., La Jolla, CA, United States
Morrissey, James H., San Diego, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 5223427 19930629
AI US 1988-165939 19880309 (7)
RLI Continuation-in-part of Ser. No. US 1987-33047, filed on 31 Mar 1987 And Ser. No. US 1987-67103, filed on 25 Jun 1987
DT Utility
FS Granted
EXNAM Primary Examiner: Nucker, Christine; Assistant Examiner: Cunningham, T.
LREP Bingham, Douglas A.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 22 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 3075
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Murine hybridomas producing monoclonal antibodies capable of immunoreacting with huTFh and polypeptide analogs are described. Also contemplated are immunologic methods for detecting huTF heavy chain in body fluid, detecting thrombic events in vivo, isolating coagulation factor, and neutralizing VII/VIIa coagulation factor binding in vivo.

L13 ANSWER 7 OF 8 USPATFULL on STN

AN 92:36115 USPATFULL
TI Human tissue factor related DNA segments
IN Edgington, Thomas S., La Jolla, CA, United States
Morrissey, James H., San Diego, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 5110730 19920505
AI US 1987-67103 19870625 (7)
RLI Continuation-in-part of Ser. No. US 1987-33047, filed on 31 Mar 1987, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Moore, William W.
LREP Bingham, Douglas A.
CLMN Number of Claims: 7
ECL Exemplary Claim: 6
DRWN 15 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 2492
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB DNA segments include DNA sequences defining a structural gene coding for a human tissue factor heavy chain **protein** and a precursor form of that **protein** are disclosed. Recombinant DNA molecules capable of expressing a human tissue factor heavy chain **protein** are also disclosed. Further disclosed are human tissue factor heavy chain binding site polypeptide analogs as well as methods for their use.

L13 ANSWER 8 OF 8 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
AN 2002-170918 [22] WPIDS
CR 1999-311709 [26]
DNN N2002-130028 DNC C2002-052716
TI **Preparation** of **protein** sample solution involves treating **protein** solution with **protein-precipitation** agents containing acidic agent, **salt** and **precipitate** forming agent.
DC B04 J04 S03
IN ALAM, A
PA (ALAM-I) ALAM A
CYC 1
PI US 2001034066 A1 20011025 (200222)* 23p
ADT US 2001034066 A1 CIP of US 1997-965873 19971107, Div ex US 1997-965873 19971107, CIP of US 1998-223738 19981231, CIP of US 1999-249499 19990212, Div ex US 2000-507977 20000222, US 2001-842838 20010427
FDT US 2001034066 A1 CIP of US 5900376, Div ex US 5900376
PRAI US 2000-507977 20000222; US 1997-965873 19971107; US 1998-223738 19981231; US 1999-249499 19990212; US 2001-842838 20010427
AB US2001034066 A UPAB: 20020409
NOVELTY - A **protein** sample solution is **prepared** by treating a **protein** solution with a **protein-precipitation** agent containing an acidic agent, **salt** and a **precipitate** forming agent. After **precipitation**, the **protein precipitate** is washed with a water miscible **organic solvent** agent to remove non-**protein** agents present in the **protein precipitate**.

DETAILED DESCRIPTION - **Preparation** of **protein** sample solution for analysis involves:

(a) treating the **protein** sample solution with an acidic agent(s), such as, **salt** and **precipitate**-forming agent;

(b) centrifuging the **protein** sample solution at least one once to form a tight pellet at the bottom of the tube, remove and discard the supernatant and cooled a **protein** pellet;

(c) suspending and mixing the **protein** pellet at least once in a medium, such as, a mixture of aqueous-**organic solvent** and **organic solvent**;

(d) centrifuging the **protein** pellet suspension and collecting the **protein** pellet; and

(e) suspending the **protein** pellet in a **protein** pellet **solubilization** reagent buffer.

The reagent buffer is provided with an acid **neutralizing agent** in a sufficient amount to neutralize the acid captured in the **protein** pellet to facilitate a desired **protein solubilization**. The **protein** sample solution contains non-**protein** agents, such as, **anionic detergent**, **cationic detergent**, **non-ionic detergent**, **zwitterionic detergent**, sulfobutane, lipid, natural product, **salt** or common laboratory agent. After **preparing** the **protein** sample, the **protein** in the sample is recovered and is free from non-**protein** agents originally present in the sample.

An INDEPENDENT CLAIM is also included for a method of total **protein assay** comprising:

(i) treating the **protein** sample solution with an acidic agent;

(ii) centrifuging the **protein** sample solution to form a tight pellet at the bottom of the tube, removing and discarding the supernatant and collecting the **protein** pellet;

(iii) suspending the **protein** pellet of step (b) with alkaline reagents of a **protein assay** to produce a characteristic **protein** reaction; and

(iv) comparing the color density of the **protein** color reaction with the color density of a **protein** reaction of known **protein** concentration.

USE - For **preparing protein** sample solution.

ADVANTAGE - The invention is rapid and results in quantitative recovery of **protein** after the procedure. The interference from non-**protein** agents present in the **protein** solutions containing detergents is developed.

Dwg.0/10

```
=> s Alam Aftab?/au
L14          62 ALAM AFTAB?/AU

=> s l11 and l14
L15           1 L11 AND L14

=> d l15 bib ab

L15  ANSWER 1 OF 1  USPATFULL on STN
AN      2001:188434  USPATFULL
TI      Agent for protein precipitation, a method of protein
        precipitation, a method of protein assay using protein
        precipitation agent, and a kit for protein assay
IN      Alam, Aftab, St. Louis, MO, United States
PI      US 2001034066       A1   20011025
AI      US 2001-842838      A1   20010427 (9)
RLI     Continuation-in-part of Ser. No. US 1998-223738, filed on 31 Dec 1998,
        PENDING Division of Ser. No. US 1997-965873, filed on 7 Nov 1997,
        GRANTED, Pat. No. US 5900376 Division of Ser. No. US 2000-507977, filed
        on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-249499,
        filed on 12 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US
        1997-965873, filed on 7 Nov 1997, GRANTED, Pat. No. US 5900376
DT      Utility
FS      APPLICATION
LREP    ARENT FOX KINTNER PLOTKIN & KAHN, 1050 CONNECTICUT AVENUE, N.W., SUITE
        600, WASHINGTON, DC, 20036
CLMN    Number of Claims: 23
ECL     Exemplary Claim: 1
DRWN    9 Drawing Page(s)
LN.CNT 1323
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

AB A method of **protein precipitation**, concentration and removal of non-**protein** agents from the **protein** solution wherein the **protein** solution is treated with a **protein-precipitation** agent containing an acidic agent, a **salt** and a **precipitate** forming agent. After **precipitation**, the **protein precipitate** is washed with a water miscible **organic solvent** agent to remove non-**protein** agents present in the **protein precipitate**.

=> dis his

(FILE 'HOME' ENTERED AT 16:02:03 ON 06 SEP 2003)

FILE 'REGISTRY' ENTERED AT 16:02:16 ON 06 SEP 2003
L1 0 S (ANIONIC DETERGENT OR CATIONIC DETERGENT OR NON-IONIC DETERGE
L2 2 S (ORGANIC SOLVENT OR ACETONE OR ALCOHOL)/CN
L3 0 S (CHOLATE OR DEOXYCHOLATE)/CN

FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS' ENTERED AT 16:07:13 ON 06 SEP 2003
L4 13872 S (ANIONIC DETERGENT OR CATIONIC DETERGENT OR NON-IONIC DETERGE
L5 783059 S (ORGANIC SOLVENT OR ACETONE OR ALCOHOL AND L2)
L6 1502 S L4 AND L5
L7 88 S L6 AND (CHOLATE OR DEOXYCHOLATE)
L8 87 S L7 AND (PROTEIN(3L)PREPAR? OR MAK? OR PURIF? OR PRECIPITAT?
L9 45 S L8 AND (SOLUBILIZ? OR NEUTRALIZ? AGENT)
L10 34 S L9 AND (SODIUM DODECYL SULFATE OR SDS)
L11 30 S L10 AND (SALT#)
L12 5 S L11 AND (POLYSACCHARIDE)
L13 8 S L11 AND (PROTEIN ASSAY)
L14 62 S ALAM AFTAB?/AU
L15 1 S L11 AND L14

=> s l10 and l14
L16 1 L10 AND L14

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 16:26:44 ON 06 SEP 2003